Sequent Scientific reported 13.21% growth in total revenues for the Dec-20 quarter on consolidated basis at Rs358.22cr. For the quarter, there was strong growth seen across formulations and also active pharma ingredients (APIs). While the formulations business grew 15% in top line, the API business grew by 17.2% on a yoy basis.
The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 64.96% at Rs39.69cr on the back of much more efficient working capital management as well as a spurt in other income in the quarter. As a result, the PAT margins improved from 7.60% in Dec-19 to 11.08% in Dec-20.
Financial highlights for Dec-20 compared yoy and sequentially
|
|
Sequent Scientific |
|
|
|
|
|
Rs in Crore |
Dec-20 |
Dec-19 |
YOY |
Sep-20 |
QOQ |
|
Total Income (Rs cr) |
₹ 358.22 |
₹ 316.42 |
13.21% |
₹ 346.27 |
3.45% |
|
Net Profit (Rs cr) |
₹ 39.69 |
₹ 24.06 |
64.96% |
₹ 21.36 |
85.81% |
|
|
|
|
|
|
|
|
Diluted EPS (Rs) |
₹ 1.52 |
₹ 0.83 |
|
₹ 0.86 |
|
|
Net Margins |
11.08% |
7.60% |
|
6.17% |
|
Related Tags: